Neoantigen heterogeneity: a key driver of immune response and sensitivity to immune checkpoint blockade?

Immunotherapy. 2016 Jun;8(7):763-6. doi: 10.2217/imt-2016-0064.
No abstract available

Keywords: CTLA-4; PD-1; heterogeneity; neoantigens.

Publication types

  • Editorial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Monoclonal / therapeutic use*
  • Antigens, Neoplasm / immunology*
  • B7-H1 Antigen / immunology
  • Biomarkers, Pharmacological / metabolism*
  • CTLA-4 Antigen / immunology
  • Drug Resistance, Neoplasm
  • Humans
  • Immunity, Cellular
  • Immunotherapy / methods*
  • Lymphocytes, Tumor-Infiltrating / immunology*
  • Lymphocytes, Tumor-Infiltrating / transplantation
  • Neoplasms / immunology
  • Neoplasms / therapy*
  • Patient Selection
  • Precision Medicine
  • Programmed Cell Death 1 Receptor / immunology
  • T-Lymphocytes / immunology*
  • T-Lymphocytes / transplantation
  • Treatment Outcome
  • United Kingdom

Substances

  • Antibodies, Monoclonal
  • Antigens, Neoplasm
  • B7-H1 Antigen
  • Biomarkers, Pharmacological
  • CTLA-4 Antigen
  • PDCD1 protein, human
  • Programmed Cell Death 1 Receptor